Back

The immunodominant and neutralization linear epitopes for SARS-CoV-2

Lu, S.; Xie, X.-x.; Zhao, L.; Wang, B.; Zhu, J.; Yang, T.-r.; Yang, G.-w.; Ji, M.; Lv, C.-p.; Xue, J.; Dai, E.-h.; Fu, X.-m.; Liu, D.-q.; Zhang, L.; Hou, S.-j.; Yu, X.-l.; Wang, Y.-l.; Gao, H.-x.; Shi, X.-h.; Ke, C.-w.; Ke, B.-x.; Jiang, C.-g.; Liu, R.-t.

2020-08-27 immunology
10.1101/2020.08.27.267716 bioRxiv
Show abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) becomes a tremendous threat to global health. Although vaccines against the virus are under development, the antigen epitopes on the virus and their immunogenicity are poorly understood. Here, we simulated the three-dimensional structures of SARS-CoV-2 proteins with high performance computer, predicted the B cell epitopes on spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of SARS-CoV-2 using structure-based approaches, and then validated the epitope immunogenicity by immunizing mice. Almost all 33 predicted epitopes effectively induced antibody production, six of which were immunodominant epitopes in patients identified via the binding of epitopes with the sera from domestic and imported COVID-19 patients, and 23 were conserved within SARS-CoV-2, SARS-CoV and bat coronavirus RaTG13. We also found that the immunodominant epitopes of domestic SARS-CoV-2 were different from that of the imported, which may be caused by the mutations on S (G614D) and N proteins. Importantly, we validated that eight epitopes on S protein elicited neutralizing antibodies that blocked the cell entry of both D614 and G614 pseudo-virus of SARS-CoV-2, three and nine epitopes induced D614 or G614 neutralizing antibodies, respectively. Our present study shed light on the immunodominance, neutralization, and conserved epitopes on SARS-CoV-2 which are potently used for the diagnosis, virus classification and the vaccine design tackling inefficiency, virus mutation and different species of coronaviruses.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Cell Discovery
57 papers in training set
Top 0.1%
9.6%
2
Science Bulletin
21 papers in training set
Top 0.1%
8.8%
3
Frontiers in Immunology
638 papers in training set
Top 2%
7.1%
4
eLife
5828 papers in training set
Top 17%
6.6%
5
Vaccines
198 papers in training set
Top 0.5%
6.6%
6
Virologica Sinica
11 papers in training set
Top 0.1%
5.4%
7
Protein & Cell
25 papers in training set
Top 0.1%
4.0%
8
Emerging Microbes & Infections
74 papers in training set
Top 0.3%
3.2%
50% of probability mass above
9
Signal Transduction and Targeted Therapy
30 papers in training set
Top 0.1%
3.2%
10
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.1%
2.7%
11
The Innovation
13 papers in training set
Top 0.1%
2.7%
12
Microbiology Spectrum
469 papers in training set
Top 5%
2.6%
13
Vaccine
203 papers in training set
Top 1.0%
2.6%
14
iScience
1154 papers in training set
Top 9%
2.6%
15
Cellular & Molecular Immunology
14 papers in training set
Top 0.1%
2.1%
16
Antiviral Research
50 papers in training set
Top 0.4%
1.7%
17
Cell Research
51 papers in training set
Top 0.5%
1.7%
18
PLOS ONE
5266 papers in training set
Top 50%
1.7%
19
Journal of Virology
499 papers in training set
Top 2%
1.7%
20
PLOS Pathogens
820 papers in training set
Top 7%
1.4%
21
Scientific Reports
3612 papers in training set
Top 62%
1.3%
22
Frontiers in Microbiology
427 papers in training set
Top 7%
1.1%
23
Journal of Medical Virology
140 papers in training set
Top 2%
1.1%
24
Antibody Therapeutics
16 papers in training set
Top 0.2%
0.9%
25
Molecular Immunology
14 papers in training set
Top 0.2%
0.9%
26
Cell Reports
1498 papers in training set
Top 28%
0.8%
27
eBioMedicine
183 papers in training set
Top 8%
0.6%
28
Journal of Immunology Research
12 papers in training set
Top 0.6%
0.6%
29
Acta Pharmaceutica Sinica B
11 papers in training set
Top 0.4%
0.6%
30
Biochemical and Biophysical Research Communications
84 papers in training set
Top 3%
0.6%